Dosage (%) | Duration of study (days) | Positive performance | Reference |
---|---|---|---|
0.05 | 17 | Increased growth performance; decreased incidence of diarrhea; improved neutrophils and lymphocytes; upregulated the expression of CLDN-1 | [ |
0.01 | 42 | Increased ADG in poor sanitary conditions; decreased plasma TNF- | [ |
0.01 | 42 | Increased growth performance; increased plasma IgA and IgG | [ |